No Data
No Data
No Data
Express News | Bluebird bio Announces 1-for-20 Reverse Stock Split
Trending Stocks Today | PainReform Surges 67.16% Post-Market
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
Bluebird Bio Announces 1-for-20 Reverse Stock Split
Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies